CA3006285A1 - Transient transfection method for retroviral production - Google Patents
Transient transfection method for retroviral production Download PDFInfo
- Publication number
- CA3006285A1 CA3006285A1 CA3006285A CA3006285A CA3006285A1 CA 3006285 A1 CA3006285 A1 CA 3006285A1 CA 3006285 A CA3006285 A CA 3006285A CA 3006285 A CA3006285 A CA 3006285A CA 3006285 A1 CA3006285 A1 CA 3006285A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- vector
- retroviral
- acid vector
- additionally comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001177 retroviral effect Effects 0.000 title claims abstract description 121
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000003146 transient transfection Methods 0.000 title abstract description 14
- 238000004519 manufacturing process Methods 0.000 title description 18
- 239000013598 vector Substances 0.000 claims abstract description 221
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 143
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 111
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 111
- 230000010076 replication Effects 0.000 claims abstract description 46
- 102100034353 Integrase Human genes 0.000 claims abstract description 10
- 108010078428 env Gene Products Proteins 0.000 claims abstract description 10
- 101710177291 Gag polyprotein Proteins 0.000 claims abstract description 8
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 8
- 108010089520 pol Gene Products Proteins 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 133
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 239000002245 particle Substances 0.000 claims description 43
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 26
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 23
- 108700019146 Transgenes Proteins 0.000 claims description 21
- 208000031886 HIV Infections Diseases 0.000 claims description 20
- 239000012212 insulator Substances 0.000 claims description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 230000002950 deficient Effects 0.000 claims description 19
- 241001430294 unidentified retrovirus Species 0.000 claims description 17
- 210000001106 artificial yeast chromosome Anatomy 0.000 claims description 14
- 241000713666 Lentivirus Species 0.000 claims description 11
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 10
- 210000004507 artificial chromosome Anatomy 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000004520 electroporation Methods 0.000 claims description 6
- 238000003151 transfection method Methods 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- 238000001638 lipofection Methods 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 241001663880 Gammaretrovirus Species 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241001664176 Alpharetrovirus Species 0.000 claims description 3
- 241000713673 Human foamy virus Species 0.000 claims description 3
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 208000010094 Visna Diseases 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 description 30
- 230000001580 bacterial effect Effects 0.000 description 23
- 238000012546 transfer Methods 0.000 description 19
- 238000004806 packaging method and process Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 14
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 13
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 13
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 108010077544 Chromatin Proteins 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 210000003483 chromatin Anatomy 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 7
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 108010061833 Integrases Proteins 0.000 description 5
- 101710149136 Protein Vpr Proteins 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 108700005077 Viral Genes Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960003722 doxycycline Drugs 0.000 description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108700004030 rev Genes Proteins 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 101150098213 rev gene Proteins 0.000 description 3
- 101150022349 sopA gene Proteins 0.000 description 3
- 101150079130 sopB gene Proteins 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 241000951889 Autographa californica multiple nucleopolyhedrovirus Species 0.000 description 2
- 241000713826 Avian leukosis virus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100278012 Escherichia coli (strain K12) dnaG gene Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 102000012330 Integrases Human genes 0.000 description 2
- 241000713326 Jaagsiekte sheep retrovirus Species 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 101100165173 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) basS gene Proteins 0.000 description 2
- 101100018382 Shigella flexneri icsP gene Proteins 0.000 description 2
- 241000713880 Spleen focus-forming virus Species 0.000 description 2
- 101100421924 Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27) spo0C gene Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 101150004979 flmA gene Proteins 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229940037201 oris Drugs 0.000 description 2
- -1 parA Proteins 0.000 description 2
- 101150048892 parB gene Proteins 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241001231757 Betaretrovirus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000537219 Deltabaculovirus Species 0.000 description 1
- 241001663879 Deltaretrovirus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000702189 Escherichia virus Mu Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000725171 Mokola lyssavirus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 101150101654 PSR1 gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241001115394 Reston ebolavirus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 238000000530 impalefection Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 101150034434 repE gene Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
- C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520764.0A GB201520764D0 (en) | 2015-11-24 | 2015-11-24 | Transient transfection method for retroviral production |
| GB1520764.0 | 2015-11-24 | ||
| GB1609354.4 | 2016-05-26 | ||
| GBGB1609354.4A GB201609354D0 (en) | 2016-05-26 | 2016-05-26 | Transient transfection method for retroviral production |
| PCT/EP2016/078334 WO2017089307A1 (en) | 2015-11-24 | 2016-11-21 | Transient transfection method for retroviral production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3006285A1 true CA3006285A1 (en) | 2017-06-01 |
Family
ID=57348703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3006285A Pending CA3006285A1 (en) | 2015-11-24 | 2016-11-21 | Transient transfection method for retroviral production |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10450574B2 (enExample) |
| EP (1) | EP3380605A1 (enExample) |
| JP (1) | JP7110096B2 (enExample) |
| KR (1) | KR102067352B1 (enExample) |
| CN (1) | CN108291211A (enExample) |
| AU (1) | AU2016359838B2 (enExample) |
| BR (1) | BR112018010639A2 (enExample) |
| CA (1) | CA3006285A1 (enExample) |
| DE (1) | DE102016122317A1 (enExample) |
| FR (1) | FR3044017B1 (enExample) |
| IL (1) | IL259223B (enExample) |
| IT (1) | IT201600117287A1 (enExample) |
| RU (1) | RU2749717C2 (enExample) |
| SA (1) | SA518391585B1 (enExample) |
| WO (1) | WO2017089307A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986051C (fr) * | 2015-05-15 | 2023-09-26 | Vectalys | Particule retrovirale comportant au moins deux arn non viraux encapsides |
| ES2939617T3 (es) * | 2015-11-24 | 2023-04-25 | Glaxosmithkline Ip Dev Ltd | Líneas celulares estables para producción retroviral |
| GB201706121D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| GB201715052D0 (en) | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| ES2951857T3 (es) | 2017-12-22 | 2023-10-25 | Oxford Biomedica Ltd | Vector retroviral |
| GB201816919D0 (en) * | 2018-10-17 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Adeno-associated viral vector producer cell lines |
| CN110684804B (zh) * | 2019-10-15 | 2023-04-18 | 上海本导基因技术有限公司 | 递送外源rnp的慢病毒载体及其制备方法 |
| GB202004371D0 (en) | 2020-03-26 | 2020-05-13 | Glaxosmithkline Ip Dev Ltd | CAR constructs |
| GB202005096D0 (en) | 2020-04-07 | 2020-05-20 | Glaxosmithkline | Modified vectors for production of retrovirus |
| AU2021253701B2 (en) * | 2020-04-10 | 2024-05-02 | Southwest Research Institute | Three-dimensional bioreactor for viral vector production |
| CN117377691A (zh) | 2021-03-19 | 2024-01-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法 |
| CN113373266B (zh) * | 2021-06-22 | 2022-07-01 | 内蒙古农业大学 | 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法 |
| WO2024218341A1 (en) | 2023-04-19 | 2024-10-24 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for car-t and car-nk cells |
| WO2024218345A1 (en) | 2023-04-21 | 2024-10-24 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| WO1995003400A1 (en) | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
| ATE309000T1 (de) * | 1995-06-27 | 2005-11-15 | Bavarian Nordic As | Verkapselte zellen die virenpartikeln produzieren |
| AU721326B2 (en) | 1996-02-13 | 2000-06-29 | Fred Hutchinson Cancer Research Center | 10A1 retroviral packaging cells and uses thereof |
| FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
| US6277621B1 (en) | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
| PT1141315E (pt) | 1998-12-31 | 2008-05-05 | Novartis Vaccines & Diagnostic | Polipéptidos do envelope (env) de hiv modificados |
| EP1179083A4 (en) | 1999-04-22 | 2003-04-23 | Gen Hospital Corp | TRIPLE HYBRID AMPLICON VECTOR SYSTEMS FOR THE PRODUCTION OF RETROVIRUS PACKING CELL LINES |
| US6677155B1 (en) | 1999-04-22 | 2004-01-13 | The General Hospital Corporation | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
| CA2371946A1 (en) | 1999-04-29 | 2000-11-09 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
| CA2336590A1 (en) | 1999-06-07 | 2000-12-14 | Cell Genesys, Inc. | Hybrid yeast-bacteria cloning system and uses thereof |
| HK1050210B (en) | 1999-10-12 | 2007-08-24 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| WO2001091802A1 (en) | 2000-05-30 | 2001-12-06 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
| AU2001292711A1 (en) | 2000-09-18 | 2002-03-26 | Genetic Therapy, Inc. | Stress resistant retroviruses |
| US6586251B2 (en) * | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002053576A1 (en) | 2001-01-05 | 2002-07-11 | The General Hospital Corporation | Viral delivery system for infectious transfer of large genomic dna inserts |
| DE10111433A1 (de) | 2001-03-09 | 2002-09-19 | Bundesrepublik Deutschland Let | Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen |
| IL157746A0 (en) | 2001-05-30 | 2004-03-28 | Chromos Molecular Systems Inc | Chromosome-based platforms |
| US6835568B2 (en) | 2001-10-30 | 2004-12-28 | Virxsys Corporation | Regulated nucleic acid expression system |
| JP4598398B2 (ja) | 2002-02-01 | 2010-12-15 | オックスフォード バイオメディカ （ユーケー） リミテッド | ウイルスベクター |
| ATE471382T1 (de) | 2002-04-10 | 2010-07-15 | Us Gov Health & Human Serv | Vac-bac-shuttlevektor-system |
| DE60314541T2 (de) * | 2002-11-25 | 2008-02-28 | Bavarian Nordic A/S | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus |
| EP1743028A2 (en) * | 2004-04-28 | 2007-01-17 | The Trustees Of The University Of Pennsylvania | Polyvalent viral vectors and a system for production thereof |
| US20080226677A1 (en) | 2004-05-06 | 2008-09-18 | Yasuko Mori | Recombinant virus vector for gene transfer into lymphoid cells |
| EP1652932A1 (en) | 2004-11-02 | 2006-05-03 | GBF Gesellschaft für Biotechnologische Forschung mbH | Method for the generation of virus producing cell lines and cell lines |
| AU2005309485A1 (en) | 2004-11-24 | 2006-06-01 | Nanovector Limited | Viral vectors |
| PT2088193E (pt) * | 2004-11-24 | 2011-02-24 | Anaeropharma Science Inc | Novo vector vaivém |
| EP2062246A4 (en) | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| EP2137296A2 (en) | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| US20110027313A1 (en) | 2008-04-04 | 2011-02-03 | University Of Miami | Viral recombineering and uses thereof |
| SI2480678T1 (sl) * | 2010-09-02 | 2014-06-30 | Molmed Spa | Stabilno proizvajanje lentivirusnih vektorjev |
| US9273324B2 (en) | 2010-12-05 | 2016-03-01 | Andrew S. Belmont | Recombinant gene expression |
| WO2012170431A2 (en) | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| JP2015529466A (ja) | 2012-09-14 | 2015-10-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター |
| US10590433B2 (en) * | 2014-03-14 | 2020-03-17 | University Of Washington | Genomic insulator elements and uses thereof |
| GB2538324A (en) | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Packaging cell line for retroviral production |
| GB2538321A (en) | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Artificial chromosome for retroviral production |
| KR102058113B1 (ko) * | 2015-11-23 | 2019-12-23 | 주식회사 엘지화학 | 접착력이 개선된 리튬 이차전지용 전극 및 이의 제조방법 |
| ES2939617T3 (es) | 2015-11-24 | 2023-04-25 | Glaxosmithkline Ip Dev Ltd | Líneas celulares estables para producción retroviral |
-
2016
- 2016-11-21 FR FR1661254A patent/FR3044017B1/fr not_active Expired - Fee Related
- 2016-11-21 US US15/356,813 patent/US10450574B2/en active Active
- 2016-11-21 JP JP2018526787A patent/JP7110096B2/ja active Active
- 2016-11-21 BR BR112018010639A patent/BR112018010639A2/pt not_active Application Discontinuation
- 2016-11-21 RU RU2018118964A patent/RU2749717C2/ru active
- 2016-11-21 WO PCT/EP2016/078334 patent/WO2017089307A1/en not_active Ceased
- 2016-11-21 KR KR1020187014239A patent/KR102067352B1/ko not_active Expired - Fee Related
- 2016-11-21 CN CN201680068697.3A patent/CN108291211A/zh active Pending
- 2016-11-21 DE DE102016122317.4A patent/DE102016122317A1/de not_active Withdrawn
- 2016-11-21 AU AU2016359838A patent/AU2016359838B2/en not_active Ceased
- 2016-11-21 CA CA3006285A patent/CA3006285A1/en active Pending
- 2016-11-21 EP EP16798223.0A patent/EP3380605A1/en not_active Withdrawn
- 2016-11-21 IT IT102016000117287A patent/IT201600117287A1/it unknown
-
2018
- 2018-05-08 IL IL259223A patent/IL259223B/en unknown
- 2018-05-15 SA SA518391585A patent/SA518391585B1/ar unknown
-
2019
- 2019-10-21 US US16/658,293 patent/US20200063144A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018010639A2 (pt) | 2019-01-22 |
| RU2749717C2 (ru) | 2021-06-16 |
| FR3044017B1 (fr) | 2019-05-03 |
| CN108291211A (zh) | 2018-07-17 |
| AU2016359838B2 (en) | 2020-08-06 |
| IL259223A (en) | 2018-07-31 |
| RU2018118964A3 (enExample) | 2020-04-02 |
| FR3044017A1 (fr) | 2017-05-26 |
| US20200063144A1 (en) | 2020-02-27 |
| DE102016122317A1 (de) | 2017-05-24 |
| US20170145427A1 (en) | 2017-05-25 |
| KR20180073624A (ko) | 2018-07-02 |
| US10450574B2 (en) | 2019-10-22 |
| WO2017089307A1 (en) | 2017-06-01 |
| SA518391585B1 (ar) | 2020-10-26 |
| EP3380605A1 (en) | 2018-10-03 |
| IL259223B (en) | 2022-05-01 |
| KR102067352B1 (ko) | 2020-01-16 |
| IT201600117287A1 (it) | 2018-05-21 |
| RU2018118964A (ru) | 2019-12-26 |
| AU2016359838A1 (en) | 2018-05-24 |
| JP2019500030A (ja) | 2019-01-10 |
| JP7110096B2 (ja) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10450574B2 (en) | Transient transfection method for retroviral production | |
| AU2016360763B2 (en) | Stable cell lines for retroviral production | |
| US11795474B2 (en) | Stable cell lines for retroviral production | |
| GB2538321A (en) | Artificial chromosome for retroviral production | |
| GB2538324A (en) | Packaging cell line for retroviral production | |
| GB2544891A (en) | Transient transfection method for retroviral production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211116 |
|
| EEER | Examination request |
Effective date: 20211116 |
|
| EEER | Examination request |
Effective date: 20211116 |
|
| EEER | Examination request |
Effective date: 20211116 |
|
| EEER | Examination request |
Effective date: 20211116 |
|
| EEER | Examination request |
Effective date: 20211116 |